Op-Ed By: Stacy Snow Feiler — Retired Public Policy Activist, former owner of LibertyTreeConsulting, specializing in public policy consulting
The new U.S.-U.K. pharmaceutical agreement is an important reminder that there is a smarter way to address global drug-pricing disparities than by importing artificial price controls into the United States. If the goal is to make medicines more affordable without undermining the innovation pipeline, trade policy that pressures foreign governments to pay more for the research and development they benefit from is far preferable to Most Favored Nation-style pricing rules that cap what Americans pay by reference to the lowest foreign price.
At its core, this debate is about who funds the extraordinary cost of pharmaceutical innovation. The United States has long shouldered a disproportionate share of that burden, in part because other wealthy nations have used reference pricing, reimbursement controls, and rebate systems that keep their prices low while allowing their patients to benefit from American-led innovation. The Trump administration’s deal with the United Kingdom moves in the opposite direction from MFN: instead of forcing U.S. prices down to European levels, it pushes a major trading partner to pay more for new medicines and to reduce the hidden clawbacks and rebate demands that have distorted access and discouraged investment.
That distinction matters. MFN is a blunt instrument. It is essentially a price-control regime dressed up as fairness, and price controls have a long record of producing the wrong incentives in pharmaceuticals. Lower drug prices can reduce R&D investment, slow pipeline development, and lead to fewer approvals over time. In plain terms, if policymakers squeeze the revenue that funds research, fewer breakthroughs make it to patients. That is not affordability; it is deferred scarcity.
By contrast, using trade negotiations to get allied countries to contribute more is a supply-side solution. It does not punish American innovation or force domestic patients to subsidize the rest of the world indefinitely. Instead, it asks countries that rely heavily on U.S.-developed medicines to pay a fairer share of the cost of producing them. That is a healthier model because it preserves the incentives that produce new cures while reducing the imbalance that has allowed foreign systems to benefit from American research without paying commensurately for it.
Florida has a particularly strong stake in this debate because the state is home to one of the nation’s largest senior populations, and older Floridians are among the Americans most affected by prescription drug costs. Whether in Miami-Dade, the Villages, Tampa Bay, or along the Gulf Coast, fixed-income retirees feel the impact of every policy decision that shapes drug affordability. That makes it especially important for Florida leaders to reject artificial price controls like MFN and instead support trade policies that push foreign governments to pay a fairer share of the cost of pharmaceutical innovation.
For Florida families, the issue is not abstract. Many seniors depend on medications for diabetes, heart disease, cancer, and other chronic conditions, and they need a system that keeps new treatments coming to market. A policy that squeezes the revenue needed to fund research could mean fewer breakthroughs reaching patients in Florida’s hospitals, oncology centers, and physician offices. By contrast, a trade-based approach that gets Europe and other wealthy nations to contribute more to R&D protects the innovation pipeline while addressing the global imbalance that has long left American patients paying more.
Florida also has a broader economic interest in preserving a strong pharmaceutical ecosystem. The state’s life sciences, biotech, and health care sectors benefit when companies continue investing in research, clinical trials, and manufacturing. A policy that discourages innovation by imposing foreign-style price ceilings would not only hurt patients; it would also undercut high-skill jobs and economic growth in communities across the state. Trade deals that reward innovation and demand fairer international cost sharing are much better aligned with Florida’s pro-growth, pro-patient interests.
MFN fails because it attacks the symptom instead of the cause. It assumes that drug prices are high simply because companies can charge too much. But the deeper problem is that the global system is badly misaligned: America pays more, European health systems pay less, and patients everywhere depend on an innovation engine that only works if there is enough revenue to justify the risk. If the United States unilaterally adopts MFN, it would likely reduce that engine’s output and create fewer therapies, slower launches, and greater long-term pain for patients.
Trade deals offer a better path because they recognize that affordability and innovation are not enemies. They can be complementary if the burden of paying for R&D is distributed more equitably. The U.S.-U.K. deal suggests a more disciplined approach: use American leverage to negotiate fairer contributions from wealthy allies, reduce non-tariff barriers and rebate distortions, and protect the pricing framework that underwrites breakthrough medicines. That is a far superior strategy to importing a foreign price benchmark that could weaken the entire ecosystem of medical discovery.
The lesson is simple. If other nations want access to the world’s best medicines, they should help pay for the science that creates them. Trade policy can help do that. MFN cannot. MFN would cap the reward for innovation; trade negotiations can expand the pool of contributors without undermining the incentives that bring new drugs to market in the first place. For patients, scientists, and taxpayers alike, that is the better deal.
About the Author: Stacy Snow Feiler — Retired Public Policy Activist, former owner of LibertyTreeConsulting, specializing in public policy consulting
Please make a small donation to the Tampa Free Press to help sustain independent journalism. Your contribution enables us to continue delivering high-quality, local, and national news coverage.
Sign up: Subscribe to our free newsletter for a curated selection of top stories delivered straight to your inbox
